Abstract
The clinical diagnosis of a pelvic inflammatory disease (PID) is notoriously difficult.
The incidence rate of PIDs among intrauterine device (IUD) users as reported from
different studies depends heavily on the definition used and the means available for
diagnosing PIDs. It varies by almost 10-fold from 1 per 100 to 1 per 1000 woman-years
in different publications. PID risk has been found to be 6-fold higher in the first
month after IUD insertion than it is thereafter. It is not known if the overall PID
risk in IUD users beyond the first month of IUD insertion is higher than that in nonusers;
however, if it is higher, the additional risk is small. The PID risk in IUD users
is modified by the number of sexual partners of the IUD user and that of her partner(s),
community prevalence of STDs and age of the IUD user. Bacterial vaginosis appears
not to be associated with IUD use. Overall, bacterial vaginosis is not associated
with PIDs, but specific subgroups of patients with BV that may be difficult to identify
clinically are at an increased risk for PIDs. Because of the long duration of use
of current copper IUDs, replacement of the IUD is infrequent and insertion-associated
PIDs should consequently also be less frequent. IUD use has become safer with respect
to PIDs through more effective screening and counseling procedures described in current
guidelines for the initiation of IUD use. Current guidance must be followed to preserve
the IUD as a safe contraceptive method.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Pelvic infections and sexually transmitted diseases.in: Scott J.R. Gibbs R.S. Karlan B.Y. Haney A.F. Danforth's obstetrics and gynecology. 9th ed. Lippincott Williams & Williams, Philadelphia (PA)2003: 581-603
- Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results.Sex Transm Dis. 1992; 19: 185-192
- Age-specific risks of syphilis, gonorrhea, and hospitalized pelvic inflammatory disease in sexually experienced U.S. women.Sex Transm Dis. 1984; 11: 291-2915
- Septic spontaneous abortion associated with the Dalkon Shield.in: Hefnowi F. Segal S.J. Analysis of intrauterine contraception. Biomedical Press, North Holland1975: 417
- The intrauterine device and deaths from spontaneous abortion.N Engl J Med. 1976; 295: 1155-1159
- Type of intrauterine device and the risk of pelvic inflammatory disease.Obstet Gynecol. 1983; 62: 1-6
- Milestones in intrauterine device development.Fertil Steril. 1983; 39: 141-143
- Criteria for diagnosis and grading of salpingitis.Obstet Gynecol. 1983; 61: 113-114
- Diagnosis of pelvic inflammatory disease: time for a rethink.Sex Transm Infect. 2003; 79: 491-494
- Sexually transmitted diseases, pelvic inflammatory disease, and infertility: an epidemiologic update.Epidemiol Rev. 1990; 12: 199-220
- Sexually transmitted diseases treatment guidelines 2006. Pelvic inflammatory disease.([Accessed 13 September 2006])
- Randomised controlled trial of prophylactic antibiotics before insertion of intrauterine devices.Lancet. 1998; 351: 1005-1008
- Infection in non-pregnant women: incidence and risk factors in the 1980s and 1990s.in: Bardin C.W. Mishell Jr, D.R. Proceedings from the Fourth International Conference on IUDs. Butterworth-Heineman, Newton (MA)1994: 142-150
- Health during prolonged use of levonorgestrel 20 ��g/d and the copper TCu 380Ag intrauterine devices: a multicenter study.Fertil Steril. 1994; 61: 70-77
- Intrauterine devices and pelvic inflammatory disease: an international perspective.Lancet. 1992; 339: 785-788
- Pelvic inflammatory disease: guidelines for prevention and management.MMWR Recomm Rep. 1991; 40 ([Accessed 21 August 2006]): 1-25
- Post-marketing surveillance of Norplant�� contraceptive implants: I. Contraceptive efficacy and reproductive health events.Contraception. 2001; 63: 167-186
- The intrauterine device and pelvic inflammatory disease revisited: new results from the Women's Health Study.Obstet Gynecol. 1988; 72: 1-6
- Epidemiology of pelvic inflammatory disease in parous women with special reference to intrauterine device use.Br J Obstet Gynaecol. 1990; 97: 780-788
- Oral contraceptive use modifies the manifestations of pelvic inflammatory disease.Br J Obstet Gynaecol. 1986; 93: 619-624
- Hormonal and barrier contraception and risk of upper genital tract disease in the PID Evaluation and Clinical Health (PEACH) Study.Am J Obstet Gynecol. 2001; 185: 121-127
- Decreased risk of symptomatic chlamydial pelvic inflammatory disease associated with oral contraceptive use.JAMA. 1990; 264: 2072-2074
- Barrier-method contraceptives and pelvic inflammatory disease.JAMA. 1982; 248: 184-187
- Scientific evidence on condom effectiveness for sexually transmitted disease (STD) prevention.([Accessed 15 October 2006])
- Evaluation of intrauterine devices: ninth progress report of the Cooperative Statistical Programme.Stud Fam Plann. 1970; 1: 1-40
- Mechanism of action, safety, and efficacy of intrauterine devices.World Health Organ Tech Rep Ser. 753. WHO, Geneva1987
- Intrauterine device and upper-genital-tract infection.Lancet. 2000; 356: 1013-1019
- The effect of different types of intrauterine devices on the risk of pelvic inflammatory disease.JAMA. 1983; 250: 759-762
- Interval IUD insertion in parous women: a randomized multicentre comparative trial of the Lippes loop D, TCu 220C and the copper 7.Contraception. 1982; 26: 1-22
- Randomized clinical study of the T-Cu 380A and the Lippes loop C in Campinas, Brazil.Contraception. 1982; 26: 221-228
- A comparative clinical trial of the TCu 380A, Lippes loop D, and Multiload Cu 375 IUDs in Indonesia.Contraception. 1991; 44: 141-154
- Clinical performance of the TCu 380A and Lippes loop IUDs in three developing countries.Contraception. 1995; 52: 17-22
- Intrauterine devices and infertility.Lancet. 2001; 358: 6-7
- Instructions for the insertion of an intra-uterine loop.in: Tietze C. Lewitt S. Proceedings of the Conference Intra-uterine Contraceptive Devices, April 1962, New York. Excerpta Medica Foundation, Amsterdam1962: 145-146
- Clinical aspects of intrauterine contraception: circumspection 1976.Fertil Steril. 1977; 28: 3-27
- Medical eligibility criteria for contraceptive use.3rd ed. World Health Organization, Geneva2004
- Bacterial vaginosis and contraceptive methods.Int J Gynaecol Obstet. 2000; 70: 341-346
- High rate of bacterial vaginosis among women with intrauterine devices in Manado, Indonesia.Contraception. 2001; 64: 169-172
- Prevalence of bacterial vaginosis and its association with genital infections, inflammation, and contraceptive methods in women attending sexually disease and primary health clinics.Int J STD AIDS. 1990; 2: 86-94
- Incidence of uncomplicated genital infection in women using oral contraception or an intrauterine device: a prospective study.Sex Transm Dis. 1990; 17: 23-29
- Sexually transmitted diseases and reproductive tract infections among contraceptive users.Int J Gynaecol Obstet. 1998; 63: S167-S173
- Contraceptive use in women with bacterial vaginosis.Contraception. 1997; 55: 355-358
- Clinical manifestations and diagnosis of pelvic inflammatory disease.J Reprod Med. 1983; 26: 703-708
- Bacterial vaginosis and risk of pelvic inflammatory disease.Obstet Gynecol. 2004; 104: 761-769
- Cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease.Am J Epidemiol. 2005; 162: 585-590
Article info
Publication history
Published online: February 19, 2007
Accepted:
December 16,
2006
Received:
November 17,
2006
Identification
Copyright
© 2007 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
